Background: Major Depressive Disorder (MDD) is a significant global health concern, with various therapeutic modalities available for its management. Understanding the relative efficacy of different treatments is crucial for optimized patient care. Objective: To compare the efficacy of Cognitive Behavioral Therapy (CBT) and pharmacological treatment in individuals diagnosed with MDD, focusing on immediate efficacy, symptom reduction, patient satisfaction, treatment adherence, and quality of life. Methods: This cross-sectional study involved 120 participants diagnosed with MDD, equally divided into two groups: one receiving CBT and the other pharmacological treatment. Data were collected on efficacy rates, reduction in depressive symptoms, patient satisfaction, adherence to treatment, and quality of life impact. Statistical analysis was conducted using chi-square tests for categorical data and independent t-tests for continuous variables, with a significance level set at p<0.05. Results: The study revealed that CBT had a significantly higher efficacy rate (52%) compared to medication (35%), with a p-value of 0.032. Although medication showed a higher reduction in depressive symptoms initially, CBT patients reported greater satisfaction (87% vs. 79%) and treatment adherence (78% vs. 55%). Quality of life scores were also significantly higher in the CBT group (70 vs. 60). Conclusion: CBT demonstrated superior overall efficacy compared to medication in the treatment of MDD, particularly in terms of patient satisfaction, adherence, and quality of life. These findings suggest that CBT might offer more comprehensive long-term benefits for managing depression.

Cognitive Behavioral Therapy, Major Depressive Disorder, Pharmacotherapy